In contrast to the view proposed by Dr Mehta in the commentary[1][1] accompanying the case-control study of peripheral blood stem cell transplantation (PBSCT) versus conventional therapy for AL (primary) amyloidosis reported by Dispenzieri et al,[2][2] we believe that the role of high-dose therapy
No takes yet. Share an insight, caveat, or question.
Goodman et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: